



# Bal Pharma Limited

Public Manager-Listing Compliance  
National Stock Exchange of India Ltd  
Mumbai.

25.01.2023

BSE Limited  
Mumbai.

Dear Sir,

**Sub: Notice for the Board Meeting.**  
**Ref: Regulation 29 of SEBI(LODR) Regulations, 2015.**

With reference to the above, Notice is hereby given that the meeting of Board of Directors of the Company is scheduled to be held on **12<sup>th</sup> February 2024 i.e on Monday** to *inter alia* consider transacting the following business.


1. Approval of Un-audited Standalone and Consolidated financial results of the Company for the quarter and nine months ended 31.12.2023.
2. To consider investing additional capital in expanding its manufacturing presence, through a green field project.

Further, pursuant to amended provisions of SEBI (Prohibition of Insider Trading Regulations), 2015 and as per the Code of Conduct of the Company, the trading window for dealing in securities of the Company by its designated persons/employees and their immediate relatives was closed from 01.01.2024 up to 14.02.2024 i.e 48 hours after declaration of financial results of the Company, for the quarter and nine months ended 31.12.2023.

Please take this intimation on record.

Thanking You.

For Bal Pharma Ltd

  
Shailesh Siroya  
Authorized Signatory



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. : 080-41570811 / 13 / 19 Fax : 41570820